glp-1/gip/gcg receptor agonist GLP-1 Orals and Multi-Agonists: Advancing Next-Gen Weight Loss Therapies with Humanized Models Dual GIP/GLP-1 receptor agonists: New

Description

The incretin hormone glucagon-like peptide 1 (GLP-1) has been implicated in the gutrenal axis and incretin-based therapies might reduce the burden of diabetic kidney disease

Janet Klein, MS RDN, CDN, CDCES, Bariatric Surgery and Obesity Medicine Program Director

We explore the underlying biological mechanisms, summarize clinical trial evidence, and highlight emerging applications in non-diabetic populations

Get Supergut Prebiotic Shake, Vanilla delivered to you in as fast as 1 hour with Bristol Farms same-day delivery.

While other GLP-1R agonists have shown promising outcomes in mitigating cancer progression, the association between some GLP-1R agonists and an increased risk of cancer remains a topic requiring more profound investigation